| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neovascularization, Pathologic | 49 | 2019 | 2631 | 3.250 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 12 | 2017 | 548 | 1.600 |
Why?
|
| Capillary Permeability | 18 | 2016 | 768 | 1.550 |
Why?
|
| Vascular Endothelial Growth Factor A | 30 | 2023 | 3513 | 1.530 |
Why?
|
| Neoplasms, Experimental | 15 | 2020 | 1229 | 1.410 |
Why?
|
| Neoplasms | 48 | 2024 | 22340 | 1.320 |
Why?
|
| Quantum Dots | 10 | 2015 | 168 | 1.040 |
Why?
|
| Mice | 142 | 2024 | 81818 | 1.000 |
Why?
|
| Endothelial Growth Factors | 14 | 2002 | 680 | 0.950 |
Why?
|
| Neovascularization, Physiologic | 11 | 2013 | 1375 | 0.940 |
Why?
|
| Lymphokines | 13 | 2011 | 911 | 0.930 |
Why?
|
| Nitric Oxide | 19 | 2009 | 2143 | 0.890 |
Why?
|
| Animals | 198 | 2024 | 168759 | 0.840 |
Why?
|
| Extracellular Fluid | 3 | 2013 | 165 | 0.830 |
Why?
|
| Physical Conditioning, Animal | 2 | 2024 | 365 | 0.830 |
Why?
|
| Lymphography | 5 | 2012 | 189 | 0.820 |
Why?
|
| Blood Vessels | 16 | 2018 | 1113 | 0.800 |
Why?
|
| Ear | 2 | 2012 | 172 | 0.770 |
Why?
|
| Mammary Neoplasms, Experimental | 13 | 2021 | 498 | 0.760 |
Why?
|
| Mice, SCID | 28 | 2017 | 2630 | 0.760 |
Why?
|
| Neoplasm Metastasis | 15 | 2015 | 4893 | 0.740 |
Why?
|
| Mammary Glands, Animal | 2 | 2012 | 272 | 0.720 |
Why?
|
| Microscopy, Fluorescence | 17 | 2018 | 2627 | 0.710 |
Why?
|
| Angiogenesis Inhibitors | 14 | 2019 | 2056 | 0.710 |
Why?
|
| Metformin | 4 | 2018 | 904 | 0.690 |
Why?
|
| Receptors, CXCR3 | 1 | 2021 | 240 | 0.670 |
Why?
|
| Antigens, Ly | 2 | 2017 | 296 | 0.650 |
Why?
|
| Fluorescent Dyes | 12 | 2018 | 1930 | 0.640 |
Why?
|
| Running | 1 | 2024 | 488 | 0.640 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 6 | 2016 | 561 | 0.630 |
Why?
|
| Pancreatic Neoplasms | 7 | 2023 | 5444 | 0.630 |
Why?
|
| Breast Implants | 2 | 2012 | 411 | 0.620 |
Why?
|
| Vascular Endothelial Growth Factors | 15 | 2023 | 754 | 0.610 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2021 | 5337 | 0.600 |
Why?
|
| Endothelial Cells | 16 | 2022 | 3584 | 0.600 |
Why?
|
| Receptors, CXCR4 | 4 | 2017 | 728 | 0.600 |
Why?
|
| Vesicular Transport Proteins | 2 | 2018 | 376 | 0.590 |
Why?
|
| Monocytes | 2 | 2017 | 2595 | 0.580 |
Why?
|
| Exercise Therapy | 2 | 2024 | 937 | 0.580 |
Why?
|
| Microcirculation | 20 | 2010 | 1280 | 0.580 |
Why?
|
| Tumor Microenvironment | 18 | 2024 | 3946 | 0.580 |
Why?
|
| Leukocytes | 17 | 2013 | 2027 | 0.540 |
Why?
|
| Argininosuccinate Synthase | 1 | 2016 | 16 | 0.530 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2024 | 4642 | 0.530 |
Why?
|
| Receptors, Chemokine | 2 | 2017 | 651 | 0.520 |
Why?
|
| Melanoma, Experimental | 5 | 2010 | 558 | 0.520 |
Why?
|
| Nanoparticles | 9 | 2017 | 1964 | 0.510 |
Why?
|
| Microscopy | 6 | 2022 | 901 | 0.510 |
Why?
|
| Pancreatic Stellate Cells | 1 | 2015 | 28 | 0.500 |
Why?
|
| Brain Neoplasms | 19 | 2021 | 9071 | 0.490 |
Why?
|
| Tail | 3 | 2012 | 91 | 0.490 |
Why?
|
| Hydrolases | 1 | 2016 | 146 | 0.490 |
Why?
|
| Macrophages | 5 | 2016 | 5772 | 0.490 |
Why?
|
| Glioblastoma | 11 | 2023 | 3459 | 0.490 |
Why?
|
| Skin Physiological Phenomena | 1 | 2016 | 193 | 0.470 |
Why?
|
| Breast Neoplasms | 20 | 2021 | 21056 | 0.470 |
Why?
|
| Oxygen | 10 | 2022 | 4241 | 0.470 |
Why?
|
| Staining and Labeling | 6 | 2013 | 1072 | 0.460 |
Why?
|
| Cell Line, Tumor | 28 | 2021 | 17075 | 0.440 |
Why?
|
| Nitric Oxide Synthase | 11 | 2006 | 911 | 0.440 |
Why?
|
| Arginine | 5 | 2016 | 933 | 0.440 |
Why?
|
| Tissue Engineering | 9 | 2015 | 1855 | 0.420 |
Why?
|
| Gastric Mucosa | 12 | 1996 | 602 | 0.410 |
Why?
|
| Nitric Oxide Synthase Type III | 7 | 2013 | 707 | 0.410 |
Why?
|
| Serum Albumin | 1 | 2016 | 675 | 0.400 |
Why?
|
| Neoplasm Transplantation | 16 | 2013 | 2014 | 0.400 |
Why?
|
| Adipose Tissue | 4 | 2016 | 3312 | 0.400 |
Why?
|
| Lymphatic Vessels | 6 | 2018 | 355 | 0.390 |
Why?
|
| Parabiosis | 1 | 2012 | 65 | 0.390 |
Why?
|
| Platelet-Derived Growth Factor | 3 | 2011 | 615 | 0.390 |
Why?
|
| Drug Delivery Systems | 9 | 2018 | 2207 | 0.390 |
Why?
|
| Anterior Chamber | 1 | 2012 | 194 | 0.380 |
Why?
|
| Neutrophils | 10 | 2017 | 3776 | 0.380 |
Why?
|
| Disease Models, Animal | 21 | 2021 | 18294 | 0.380 |
Why?
|
| Liver Neoplasms | 5 | 2016 | 4353 | 0.370 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 6 | 2017 | 265 | 0.370 |
Why?
|
| Rodent Diseases | 1 | 2011 | 53 | 0.370 |
Why?
|
| Pregnancy Proteins | 3 | 2013 | 225 | 0.370 |
Why?
|
| Cell Communication | 7 | 2013 | 1660 | 0.370 |
Why?
|
| Liver Neoplasms, Experimental | 4 | 2021 | 190 | 0.360 |
Why?
|
| Mice, Knockout | 19 | 2022 | 14447 | 0.360 |
Why?
|
| Otologic Surgical Procedures | 1 | 2012 | 148 | 0.360 |
Why?
|
| Antineoplastic Agents | 13 | 2018 | 13648 | 0.350 |
Why?
|
| Angiopoietin-2 | 2 | 2019 | 187 | 0.350 |
Why?
|
| Green Fluorescent Proteins | 6 | 2015 | 2060 | 0.340 |
Why?
|
| Lymphangiogenesis | 5 | 2010 | 171 | 0.340 |
Why?
|
| Colorectal Neoplasms | 3 | 2021 | 6942 | 0.320 |
Why?
|
| Mice, Inbred C57BL | 22 | 2021 | 22331 | 0.320 |
Why?
|
| Antibodies | 4 | 2020 | 2417 | 0.310 |
Why?
|
| Fibrosarcoma | 2 | 2009 | 313 | 0.310 |
Why?
|
| Kupffer Cells | 9 | 1996 | 144 | 0.310 |
Why?
|
| Tumor Cells, Cultured | 16 | 2021 | 6113 | 0.310 |
Why?
|
| Mast Cells | 2 | 2016 | 1412 | 0.310 |
Why?
|
| Endothelium, Vascular | 16 | 2016 | 4427 | 0.300 |
Why?
|
| Pleural Neoplasms | 1 | 2013 | 581 | 0.290 |
Why?
|
| Stromal Cells | 8 | 2012 | 1329 | 0.290 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2008 | 178 | 0.280 |
Why?
|
| Obesity | 6 | 2018 | 13075 | 0.280 |
Why?
|
| Paracrine Communication | 3 | 2013 | 277 | 0.280 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2016 | 8611 | 0.280 |
Why?
|
| Mice, Inbred C3H | 7 | 2016 | 914 | 0.270 |
Why?
|
| Colonic Neoplasms | 9 | 2015 | 2531 | 0.270 |
Why?
|
| Platelet Activating Factor | 7 | 1996 | 142 | 0.270 |
Why?
|
| Abdomen | 1 | 2012 | 1134 | 0.270 |
Why?
|
| Skin Transplantation | 1 | 2012 | 1098 | 0.270 |
Why?
|
| Glioma | 4 | 2010 | 3493 | 0.260 |
Why?
|
| Mice, Nude | 16 | 2019 | 3618 | 0.260 |
Why?
|
| Benzylamines | 3 | 2017 | 251 | 0.260 |
Why?
|
| Thoracic Surgery | 1 | 2013 | 728 | 0.260 |
Why?
|
| Hemodynamics | 7 | 2013 | 4183 | 0.250 |
Why?
|
| Endothelins | 6 | 1996 | 127 | 0.250 |
Why?
|
| Losartan | 3 | 2023 | 263 | 0.250 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 8 | 2016 | 660 | 0.250 |
Why?
|
| Xenograft Model Antitumor Assays | 13 | 2020 | 3608 | 0.250 |
Why?
|
| Ribonuclease, Pancreatic | 2 | 2016 | 112 | 0.250 |
Why?
|
| Antibodies, Monoclonal | 11 | 2018 | 9249 | 0.240 |
Why?
|
| Luminescent Measurements | 14 | 2013 | 341 | 0.240 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 5 | 2009 | 117 | 0.240 |
Why?
|
| Lymphatic System | 5 | 2011 | 250 | 0.240 |
Why?
|
| Neoplasm Proteins | 3 | 2016 | 3596 | 0.240 |
Why?
|
| Antibodies, Neoplasm | 2 | 2016 | 282 | 0.230 |
Why?
|
| Adenocarcinoma | 9 | 2015 | 6364 | 0.230 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2017 | 2878 | 0.230 |
Why?
|
| Signal Transduction | 13 | 2021 | 23600 | 0.220 |
Why?
|
| Vascular Endothelial Growth Factor C | 5 | 2009 | 124 | 0.220 |
Why?
|
| Hydrogen-Ion Concentration | 6 | 2013 | 2477 | 0.210 |
Why?
|
| Rats, Wistar | 25 | 1997 | 1884 | 0.210 |
Why?
|
| omega-N-Methylarginine | 7 | 2009 | 108 | 0.210 |
Why?
|
| Wound Healing | 3 | 2012 | 2792 | 0.210 |
Why?
|
| Humans | 113 | 2024 | 765956 | 0.210 |
Why?
|
| Lymphatic Metastasis | 7 | 2011 | 2887 | 0.200 |
Why?
|
| Enzyme Inhibitors | 7 | 2015 | 3715 | 0.200 |
Why?
|
| Chemokine CXCL12 | 2 | 2017 | 455 | 0.200 |
Why?
|
| Rats | 38 | 2020 | 23707 | 0.200 |
Why?
|
| Immunotherapy | 5 | 2022 | 4752 | 0.200 |
Why?
|
| Quinazolines | 4 | 2016 | 1364 | 0.200 |
Why?
|
| Organometallic Compounds | 2 | 2002 | 644 | 0.190 |
Why?
|
| Microscopy, Confocal | 5 | 2010 | 1965 | 0.190 |
Why?
|
| Muscle, Smooth, Vascular | 5 | 2019 | 1499 | 0.190 |
Why?
|
| Photochemotherapy | 3 | 2003 | 826 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2004 | 1240 | 0.190 |
Why?
|
| Up-Regulation | 6 | 2017 | 4137 | 0.190 |
Why?
|
| Chemokine CXCL11 | 1 | 2021 | 43 | 0.190 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2021 | 40 | 0.190 |
Why?
|
| Fluorescein-5-isothiocyanate | 3 | 2013 | 220 | 0.180 |
Why?
|
| Photosensitizing Agents | 2 | 2002 | 625 | 0.180 |
Why?
|
| Diagnostic Imaging | 6 | 2016 | 3529 | 0.180 |
Why?
|
| Chemokine CXCL9 | 1 | 2021 | 137 | 0.180 |
Why?
|
| Radiation Tolerance | 2 | 2017 | 475 | 0.180 |
Why?
|
| Blood-Brain Barrier | 3 | 2020 | 1037 | 0.180 |
Why?
|
| Luminescent Proteins | 4 | 2009 | 839 | 0.180 |
Why?
|
| Receptors, GABA-A | 2 | 2022 | 624 | 0.180 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2021 | 429 | 0.180 |
Why?
|
| Lymph Nodes | 2 | 2009 | 3454 | 0.170 |
Why?
|
| Fibroblasts | 5 | 2015 | 4159 | 0.170 |
Why?
|
| Fibroblast Growth Factor 2 | 3 | 2018 | 594 | 0.170 |
Why?
|
| Models, Biological | 10 | 2016 | 9443 | 0.170 |
Why?
|
| Rabbits | 5 | 2012 | 4734 | 0.170 |
Why?
|
| Partial Pressure | 3 | 2013 | 245 | 0.160 |
Why?
|
| Acidosis | 1 | 2001 | 271 | 0.160 |
Why?
|
| Drug Carriers | 2 | 2015 | 700 | 0.160 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2015 | 512 | 0.160 |
Why?
|
| Osteosarcoma | 1 | 2005 | 909 | 0.160 |
Why?
|
| Nanomedicine | 2 | 2012 | 286 | 0.160 |
Why?
|
| Maytansine | 2 | 2018 | 87 | 0.160 |
Why?
|
| Dextrans | 2 | 2013 | 571 | 0.160 |
Why?
|
| Rhodamines | 5 | 2013 | 178 | 0.150 |
Why?
|
| Granulocytes | 3 | 2021 | 549 | 0.150 |
Why?
|
| Infrared Rays | 2 | 2018 | 246 | 0.150 |
Why?
|
| Cell Growth Processes | 3 | 2009 | 381 | 0.150 |
Why?
|
| Heterocyclic Compounds | 2 | 2017 | 245 | 0.150 |
Why?
|
| Carcinoma | 2 | 2008 | 2312 | 0.150 |
Why?
|
| Piperazines | 2 | 2011 | 2549 | 0.150 |
Why?
|
| Cholangiocarcinoma | 1 | 2024 | 578 | 0.150 |
Why?
|
| Mice, Transgenic | 11 | 2015 | 9550 | 0.150 |
Why?
|
| Cerebellum | 2 | 2017 | 1518 | 0.150 |
Why?
|
| Mice, Inbred BALB C | 2 | 2017 | 6220 | 0.150 |
Why?
|
| Cell Proliferation | 9 | 2017 | 10429 | 0.140 |
Why?
|
| Cisplatin | 1 | 2024 | 1658 | 0.140 |
Why?
|
| Lung Neoplasms | 10 | 2021 | 13451 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 11868 | 0.140 |
Why?
|
| Permeability | 3 | 2016 | 726 | 0.140 |
Why?
|
| Receptor, erbB-2 | 4 | 2021 | 2593 | 0.140 |
Why?
|
| Cell Division | 12 | 2006 | 4475 | 0.140 |
Why?
|
| Bone Neoplasms | 2 | 2011 | 2567 | 0.140 |
Why?
|
| Chemokine CX3CL1 | 1 | 2017 | 60 | 0.140 |
Why?
|
| Blood Vessel Prosthesis | 2 | 2013 | 912 | 0.140 |
Why?
|
| Diffusion | 4 | 2013 | 808 | 0.140 |
Why?
|
| Extracellular Matrix | 3 | 2016 | 1727 | 0.140 |
Why?
|
| NAD | 2 | 2020 | 619 | 0.140 |
Why?
|
| Transplantation, Heterologous | 8 | 2013 | 2394 | 0.140 |
Why?
|
| Cell Movement | 9 | 2015 | 5194 | 0.130 |
Why?
|
| Fluoresceins | 3 | 1995 | 234 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2017 | 5696 | 0.130 |
Why?
|
| Pyrimidines | 2 | 2011 | 3047 | 0.130 |
Why?
|
| Ornithine Carbamoyltransferase | 1 | 2016 | 25 | 0.130 |
Why?
|
| Adipocytes | 1 | 2003 | 1194 | 0.130 |
Why?
|
| Receptor, erbB-3 | 1 | 2017 | 141 | 0.130 |
Why?
|
| Cadmium Compounds | 2 | 2013 | 14 | 0.130 |
Why?
|
| Selenium Compounds | 2 | 2013 | 11 | 0.130 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2020 | 825 | 0.130 |
Why?
|
| Arteriovenous Anastomosis | 2 | 2011 | 14 | 0.130 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2021 | 720 | 0.130 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 1997 | 122 | 0.130 |
Why?
|
| Blood Flow Velocity | 10 | 2010 | 1381 | 0.130 |
Why?
|
| Arginase | 1 | 2016 | 81 | 0.130 |
Why?
|
| Lithium | 1 | 2019 | 597 | 0.120 |
Why?
|
| Metalloporphyrins | 1 | 2015 | 41 | 0.120 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2008 | 2047 | 0.120 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2016 | 153 | 0.120 |
Why?
|
| Cerebellar Diseases | 1 | 2017 | 226 | 0.120 |
Why?
|
| Biological Assay | 1 | 2018 | 627 | 0.120 |
Why?
|
| Cytomegalovirus | 1 | 2020 | 751 | 0.120 |
Why?
|
| Polyethylene Glycols | 4 | 2012 | 1188 | 0.120 |
Why?
|
| Amidines | 1 | 2015 | 28 | 0.120 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 2015 | 48 | 0.120 |
Why?
|
| Luciferases | 2 | 2009 | 713 | 0.120 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2015 | 46 | 0.120 |
Why?
|
| Endotoxemia | 1 | 1996 | 198 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 4 | 2015 | 1995 | 0.120 |
Why?
|
| Transcription, Genetic | 3 | 2004 | 7599 | 0.120 |
Why?
|
| Reperfusion Injury | 2 | 2019 | 1042 | 0.120 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2015 | 59 | 0.120 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2019 | 702 | 0.120 |
Why?
|
| Mice, Obese | 1 | 2016 | 417 | 0.120 |
Why?
|
| Sulfides | 2 | 2013 | 165 | 0.120 |
Why?
|
| Micelles | 1 | 2015 | 188 | 0.120 |
Why?
|
| Pericytes | 4 | 2015 | 299 | 0.120 |
Why?
|
| Cerebral Infarction | 1 | 2019 | 970 | 0.120 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2010 | 691 | 0.110 |
Why?
|
| Particle Size | 4 | 2011 | 1631 | 0.110 |
Why?
|
| Transfection | 5 | 2007 | 5743 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2010 | 4562 | 0.110 |
Why?
|
| Male | 62 | 2021 | 363691 | 0.110 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2016 | 869 | 0.110 |
Why?
|
| Biocompatible Materials | 3 | 2015 | 1682 | 0.110 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2013 | 25 | 0.110 |
Why?
|
| Interleukin-1 | 2 | 1996 | 1243 | 0.110 |
Why?
|
| Models, Animal | 4 | 2013 | 2120 | 0.110 |
Why?
|
| Convection | 1 | 2013 | 30 | 0.110 |
Why?
|
| Glycosaminoglycans | 1 | 2016 | 606 | 0.110 |
Why?
|
| E-Selectin | 2 | 2011 | 576 | 0.110 |
Why?
|
| Static Electricity | 2 | 2012 | 259 | 0.110 |
Why?
|
| Luminescent Agents | 1 | 2013 | 30 | 0.110 |
Why?
|
| Bone Marrow Cells | 7 | 2011 | 2412 | 0.110 |
Why?
|
| Skin | 7 | 2016 | 4489 | 0.110 |
Why?
|
| Antibodies, Bispecific | 1 | 2016 | 203 | 0.110 |
Why?
|
| Hyaluronic Acid | 1 | 2016 | 484 | 0.100 |
Why?
|
| Cell Adhesion | 12 | 2011 | 3089 | 0.100 |
Why?
|
| Interleukin-1beta | 2 | 2016 | 1028 | 0.100 |
Why?
|
| Photons | 2 | 2015 | 572 | 0.100 |
Why?
|
| Peptide Hydrolases | 1 | 2016 | 608 | 0.100 |
Why?
|
| Magnetite Nanoparticles | 1 | 2014 | 309 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 3 | 2015 | 2822 | 0.100 |
Why?
|
| Fluorescence | 4 | 2014 | 753 | 0.100 |
Why?
|
| Receptors, Growth Factor | 4 | 2002 | 324 | 0.100 |
Why?
|
| Female | 39 | 2021 | 396101 | 0.100 |
Why?
|
| Neuropilin-1 | 1 | 2013 | 90 | 0.100 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2015 | 1883 | 0.100 |
Why?
|
| Intestinal Mucosa | 6 | 2010 | 3046 | 0.100 |
Why?
|
| Microscopy, Video | 1 | 2013 | 241 | 0.100 |
Why?
|
| Animal Experimentation | 1 | 2012 | 46 | 0.100 |
Why?
|
| Endotoxins | 4 | 1996 | 516 | 0.100 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 8529 | 0.100 |
Why?
|
| Optical Phenomena | 1 | 2013 | 103 | 0.100 |
Why?
|
| Kinetics | 4 | 2012 | 6274 | 0.100 |
Why?
|
| Immunoconjugates | 1 | 2020 | 981 | 0.100 |
Why?
|
| Cyclic GMP | 1 | 2013 | 394 | 0.100 |
Why?
|
| Nanospheres | 1 | 2011 | 20 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 3 | 2001 | 5786 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 1998 | 4348 | 0.090 |
Why?
|
| Cell Survival | 7 | 2010 | 5746 | 0.090 |
Why?
|
| Receptors, Immunologic | 1 | 2018 | 1415 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 870 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 2019 | 1402 | 0.090 |
Why?
|
| Cells, Cultured | 13 | 2013 | 18973 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2016 | 4034 | 0.090 |
Why?
|
| Genes, Dominant | 2 | 2004 | 856 | 0.090 |
Why?
|
| Receptors, CXCR | 1 | 2011 | 52 | 0.090 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2013 | 416 | 0.090 |
Why?
|
| Muscle, Skeletal | 2 | 2005 | 4959 | 0.090 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 752 | 0.090 |
Why?
|
| Glucose | 3 | 2016 | 4335 | 0.090 |
Why?
|
| Cell Differentiation | 3 | 2007 | 11640 | 0.090 |
Why?
|
| Immunohistochemistry | 8 | 2010 | 11022 | 0.090 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2011 | 182 | 0.090 |
Why?
|
| Pyridinium Compounds | 6 | 1995 | 80 | 0.090 |
Why?
|
| Indium | 1 | 2010 | 46 | 0.090 |
Why?
|
| Gallbladder Neoplasms | 2 | 2004 | 189 | 0.090 |
Why?
|
| Erythrocytes | 5 | 2010 | 2395 | 0.090 |
Why?
|
| Copepoda | 1 | 2009 | 14 | 0.080 |
Why?
|
| Blotting, Western | 5 | 2015 | 5020 | 0.080 |
Why?
|
| Gelatin | 1 | 2012 | 227 | 0.080 |
Why?
|
| Vascular Diseases | 2 | 2015 | 1159 | 0.080 |
Why?
|
| Autoimmunity | 1 | 2018 | 1354 | 0.080 |
Why?
|
| Disease Progression | 8 | 2016 | 13631 | 0.080 |
Why?
|
| Microvessels | 2 | 2011 | 591 | 0.080 |
Why?
|
| Embryo, Mammalian | 1 | 2015 | 1673 | 0.080 |
Why?
|
| Molecular Imaging | 3 | 2015 | 822 | 0.080 |
Why?
|
| Drug Design | 1 | 2015 | 1042 | 0.080 |
Why?
|
| RNA, Small Interfering | 2 | 2017 | 3421 | 0.080 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2012 | 697 | 0.080 |
Why?
|
| Blotting, Northern | 2 | 2004 | 1546 | 0.080 |
Why?
|
| Blood | 1 | 2012 | 597 | 0.080 |
Why?
|
| Helicobacter pylori | 4 | 1999 | 380 | 0.080 |
Why?
|
| Myeloid Cells | 2 | 2010 | 839 | 0.080 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2010 | 153 | 0.080 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2011 | 462 | 0.080 |
Why?
|
| Inflammation | 5 | 2016 | 10850 | 0.080 |
Why?
|
| Thymus Neoplasms | 1 | 2011 | 270 | 0.080 |
Why?
|
| Molecular Probes | 1 | 2010 | 307 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2018 | 3807 | 0.070 |
Why?
|
| Vasoconstriction | 4 | 1996 | 594 | 0.070 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2010 | 239 | 0.070 |
Why?
|
| DNA Primers | 4 | 2008 | 2825 | 0.070 |
Why?
|
| Cerebellar Neoplasms | 1 | 2013 | 571 | 0.070 |
Why?
|
| Optics and Photonics | 1 | 2010 | 305 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2018 | 3222 | 0.070 |
Why?
|
| Gene Amplification | 1 | 2012 | 1091 | 0.070 |
Why?
|
| Medulloblastoma | 1 | 2013 | 658 | 0.070 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2016 | 1758 | 0.070 |
Why?
|
| Escherichia coli | 3 | 1996 | 4214 | 0.070 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2008 | 171 | 0.070 |
Why?
|
| Genes, Reporter | 2 | 2004 | 1524 | 0.070 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 3111 | 0.070 |
Why?
|
| Radiation Dosage | 1 | 2016 | 1944 | 0.070 |
Why?
|
| Metal Nanoparticles | 1 | 2011 | 403 | 0.070 |
Why?
|
| Zebrafish Proteins | 1 | 2013 | 1017 | 0.070 |
Why?
|
| Apoptosis | 8 | 2015 | 9514 | 0.070 |
Why?
|
| Regional Blood Flow | 4 | 2002 | 1478 | 0.070 |
Why?
|
| Omeprazole | 2 | 1999 | 106 | 0.070 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2002 | 1624 | 0.060 |
Why?
|
| Immunoglobulin G | 3 | 2015 | 4528 | 0.060 |
Why?
|
| Benzamides | 2 | 2011 | 1377 | 0.060 |
Why?
|
| Disease | 1 | 2011 | 676 | 0.060 |
Why?
|
| Cardiovascular System | 1 | 2013 | 841 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 2 | 2004 | 1490 | 0.060 |
Why?
|
| Zinc | 1 | 2010 | 675 | 0.060 |
Why?
|
| Adipogenesis | 1 | 2008 | 369 | 0.060 |
Why?
|
| Homeodomain Proteins | 2 | 2008 | 2428 | 0.060 |
Why?
|
| Metals | 1 | 2010 | 710 | 0.060 |
Why?
|
| Tissue Culture Techniques | 1 | 2006 | 286 | 0.060 |
Why?
|
| Microscopy, Electron | 3 | 2015 | 2548 | 0.060 |
Why?
|
| HCT116 Cells | 1 | 2006 | 399 | 0.060 |
Why?
|
| Biomimetics | 1 | 2006 | 168 | 0.060 |
Why?
|
| Prognosis | 2 | 2016 | 29921 | 0.060 |
Why?
|
| Perfusion | 4 | 2019 | 1407 | 0.060 |
Why?
|
| Imidazoles | 2 | 2010 | 1162 | 0.060 |
Why?
|
| Contrast Media | 1 | 2018 | 5329 | 0.060 |
Why?
|
| RNA, Messenger | 6 | 2004 | 12769 | 0.060 |
Why?
|
| Brain Edema | 1 | 2009 | 602 | 0.060 |
Why?
|
| Mesentery | 2 | 1997 | 199 | 0.060 |
Why?
|
| Dimerization | 1 | 2006 | 880 | 0.060 |
Why?
|
| Adenoma | 1 | 2015 | 2152 | 0.060 |
Why?
|
| Mitochondria, Liver | 2 | 1996 | 190 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 1995 | 3141 | 0.060 |
Why?
|
| Tissue Plasminogen Activator | 4 | 1994 | 1167 | 0.060 |
Why?
|
| Diffusion Chambers, Culture | 1 | 2003 | 49 | 0.060 |
Why?
|
| Rhodamine 123 | 4 | 1996 | 37 | 0.060 |
Why?
|
| Intestine, Small | 3 | 1996 | 1214 | 0.050 |
Why?
|
| Embryonic Stem Cells | 2 | 2009 | 1241 | 0.050 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2010 | 888 | 0.050 |
Why?
|
| Esophageal Neoplasms | 1 | 2013 | 1661 | 0.050 |
Why?
|
| Electric Stimulation | 4 | 1996 | 1735 | 0.050 |
Why?
|
| Gene Expression | 4 | 2005 | 7584 | 0.050 |
Why?
|
| Liposomes | 3 | 2002 | 788 | 0.050 |
Why?
|
| Tissue Distribution | 3 | 2016 | 2266 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 3110 | 0.050 |
Why?
|
| Sarcoma, Experimental | 1 | 2003 | 116 | 0.050 |
Why?
|
| Transcription Factors | 4 | 2005 | 12131 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2012 | 2054 | 0.050 |
Why?
|
| Receptors, Angiotensin | 1 | 2022 | 141 | 0.050 |
Why?
|
| 3T3 Cells | 1 | 2003 | 1081 | 0.050 |
Why?
|
| Hypertension | 1 | 2022 | 8626 | 0.050 |
Why?
|
| Angiotensins | 1 | 2022 | 139 | 0.050 |
Why?
|
| Matrix Metalloproteinases | 2 | 2020 | 392 | 0.050 |
Why?
|
| Fibrinolysis | 2 | 1994 | 331 | 0.050 |
Why?
|
| Cell Hypoxia | 2 | 2001 | 647 | 0.050 |
Why?
|
| Silicon Dioxide | 2 | 2014 | 217 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2017 | 3785 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2006 | 3796 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2003 | 735 | 0.050 |
Why?
|
| Oxidation-Reduction | 4 | 2022 | 2218 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2008 | 1505 | 0.050 |
Why?
|
| Lipopolysaccharides | 4 | 1998 | 2216 | 0.050 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2023 | 1510 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2009 | 2195 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 4850 | 0.050 |
Why?
|
| Body Weight | 2 | 2009 | 4622 | 0.050 |
Why?
|
| Endothelin-1 | 2 | 2008 | 295 | 0.050 |
Why?
|
| Skull | 3 | 2010 | 811 | 0.050 |
Why?
|
| Lasers | 2 | 2022 | 951 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2016 | 1377 | 0.050 |
Why?
|
| Leucovorin | 1 | 2023 | 641 | 0.050 |
Why?
|
| Salmonella typhimurium | 1 | 2003 | 348 | 0.050 |
Why?
|
| Laser-Doppler Flowmetry | 3 | 1996 | 236 | 0.050 |
Why?
|
| Doxorubicin | 3 | 2018 | 2230 | 0.040 |
Why?
|
| Fetal Blood | 1 | 2007 | 1369 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2004 | 700 | 0.040 |
Why?
|
| Leptin | 1 | 2009 | 1596 | 0.040 |
Why?
|
| Tropism | 1 | 2020 | 44 | 0.040 |
Why?
|
| HeLa Cells | 3 | 2012 | 3067 | 0.040 |
Why?
|
| Osmolar Concentration | 2 | 2012 | 655 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2012 | 3564 | 0.040 |
Why?
|
| Guinea Pigs | 1 | 2002 | 1300 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2013 | 8927 | 0.040 |
Why?
|
| Stem Cells | 4 | 2008 | 3540 | 0.040 |
Why?
|
| Oxidants | 3 | 1997 | 166 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2001 | 479 | 0.040 |
Why?
|
| Blood Circulation | 1 | 2001 | 248 | 0.040 |
Why?
|
| Superoxide Dismutase | 4 | 1995 | 593 | 0.040 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1999 | 116 | 0.040 |
Why?
|
| Nitrites | 2 | 1997 | 156 | 0.040 |
Why?
|
| Piperidines | 1 | 2008 | 1664 | 0.040 |
Why?
|
| Coculture Techniques | 3 | 2004 | 1336 | 0.040 |
Why?
|
| Mesenchymal Stem Cells | 2 | 2008 | 1663 | 0.040 |
Why?
|
| Ligands | 3 | 2012 | 3273 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 1996 | 1127 | 0.040 |
Why?
|
| Time Factors | 11 | 2009 | 40065 | 0.040 |
Why?
|
| Response Elements | 1 | 2000 | 307 | 0.040 |
Why?
|
| Precancerous Conditions | 1 | 2006 | 976 | 0.040 |
Why?
|
| Respiratory Burst | 3 | 1996 | 107 | 0.040 |
Why?
|
| Urease | 2 | 1996 | 43 | 0.040 |
Why?
|
| Receptor, TIE-2 | 2 | 2013 | 183 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 852 | 0.040 |
Why?
|
| Base Sequence | 3 | 2008 | 12403 | 0.040 |
Why?
|
| Cell Separation | 3 | 2015 | 1718 | 0.040 |
Why?
|
| Peyer's Patches | 2 | 1997 | 120 | 0.040 |
Why?
|
| Tomography, Optical Coherence | 1 | 2012 | 2932 | 0.040 |
Why?
|
| Nitrates | 2 | 1997 | 260 | 0.040 |
Why?
|
| Prosencephalon | 1 | 2020 | 305 | 0.040 |
Why?
|
| Stomach Ulcer | 2 | 1996 | 118 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2021 | 433 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2010 | 3737 | 0.040 |
Why?
|
| Orchiectomy | 1 | 2000 | 460 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2023 | 1648 | 0.040 |
Why?
|
| Cations | 2 | 2012 | 240 | 0.040 |
Why?
|
| Arterioles | 2 | 1996 | 251 | 0.040 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2000 | 409 | 0.040 |
Why?
|
| Stem Cell Transplantation | 2 | 2003 | 1602 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2009 | 2892 | 0.040 |
Why?
|
| Indicators and Reagents | 1 | 1998 | 457 | 0.040 |
Why?
|
| Cell Line | 6 | 2015 | 15543 | 0.040 |
Why?
|
| Nuclear Proteins | 3 | 2007 | 5783 | 0.040 |
Why?
|
| Cell Culture Techniques | 2 | 2020 | 1652 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 3 | 2010 | 2729 | 0.040 |
Why?
|
| Liver Circulation | 1 | 1997 | 163 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 1996 | 1347 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 3236 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2016 | 1885 | 0.030 |
Why?
|
| Microbubbles | 1 | 2018 | 136 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2004 | 10729 | 0.030 |
Why?
|
| Stroke | 1 | 2019 | 9747 | 0.030 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 1996 | 2329 | 0.030 |
Why?
|
| Naphthols | 1 | 1996 | 45 | 0.030 |
Why?
|
| Free Radicals | 5 | 1996 | 238 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2009 | 610 | 0.030 |
Why?
|
| Protein Kinases | 1 | 2004 | 1611 | 0.030 |
Why?
|
| Acrylates | 1 | 1996 | 75 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 4900 | 0.030 |
Why?
|
| Peptides, Cyclic | 2 | 1996 | 390 | 0.030 |
Why?
|
| Food, Formulated | 1 | 1997 | 103 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2013 | 3586 | 0.030 |
Why?
|
| Necrosis | 3 | 2012 | 1617 | 0.030 |
Why?
|
| Umbilical Veins | 2 | 2009 | 421 | 0.030 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1995 | 42 | 0.030 |
Why?
|
| Mesenteric Arteries | 2 | 1993 | 177 | 0.030 |
Why?
|
| Indocyanine Green | 1 | 2018 | 235 | 0.030 |
Why?
|
| Cytotoxins | 1 | 2016 | 154 | 0.030 |
Why?
|
| Taurocholic Acid | 1 | 1995 | 43 | 0.030 |
Why?
|
| Cholagogues and Choleretics | 1 | 1995 | 39 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2020 | 547 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 1997 | 682 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2023 | 1624 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2022 | 1140 | 0.030 |
Why?
|
| Liver | 3 | 1996 | 7562 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2011 | 8067 | 0.030 |
Why?
|
| Interferon-gamma | 2 | 2021 | 3160 | 0.030 |
Why?
|
| Peroxidase | 2 | 1995 | 606 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2005 | 2796 | 0.030 |
Why?
|
| Palladium | 1 | 2015 | 67 | 0.030 |
Why?
|
| Lung | 2 | 2011 | 10033 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2007 | 3401 | 0.030 |
Why?
|
| Fatty Acids | 2 | 2021 | 1806 | 0.030 |
Why?
|
| DNA-Binding Proteins | 3 | 2007 | 9601 | 0.030 |
Why?
|
| Capsules | 1 | 2015 | 193 | 0.030 |
Why?
|
| Splanchnic Circulation | 2 | 1992 | 122 | 0.030 |
Why?
|
| Smad2 Protein | 1 | 2015 | 144 | 0.030 |
Why?
|
| Free Radical Scavengers | 1 | 1995 | 212 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2015 | 164 | 0.030 |
Why?
|
| Rats, Inbred Strains | 5 | 1996 | 2077 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 1995 | 315 | 0.030 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2015 | 182 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2021 | 1375 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 6493 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2015 | 541 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 1801 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2021 | 2865 | 0.030 |
Why?
|
| Anti-Ulcer Agents | 1 | 1994 | 112 | 0.030 |
Why?
|
| Antithrombin III | 1 | 1994 | 128 | 0.030 |
Why?
|
| Phenotype | 4 | 2015 | 16721 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2020 | 1365 | 0.030 |
Why?
|
| Mitochondria | 3 | 1996 | 3673 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 2 | 1996 | 1612 | 0.030 |
Why?
|
| Models, Molecular | 2 | 2015 | 5379 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2022 | 1587 | 0.030 |
Why?
|
| Angiopoietin-1 | 2 | 2004 | 132 | 0.030 |
Why?
|
| Androgens | 1 | 2000 | 1279 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1997 | 910 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2004 | 8278 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2015 | 752 | 0.030 |
Why?
|
| Betaine | 1 | 2012 | 90 | 0.030 |
Why?
|
| Antinematodal Agents | 1 | 2012 | 8 | 0.030 |
Why?
|
| Enterotoxins | 1 | 1994 | 366 | 0.030 |
Why?
|
| Regenerative Medicine | 2 | 2008 | 303 | 0.020 |
Why?
|
| Cattle | 1 | 2018 | 3801 | 0.020 |
Why?
|
| Helicobacter Infections | 1 | 1996 | 390 | 0.020 |
Why?
|
| Neuroprotective Agents | 1 | 2019 | 959 | 0.020 |
Why?
|
| Oxazolone | 1 | 2011 | 59 | 0.020 |
Why?
|
| Alanine | 1 | 1994 | 612 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 1394 | 0.020 |
Why?
|
| Pathology, Molecular | 1 | 2015 | 330 | 0.020 |
Why?
|
| Ammonia | 1 | 1992 | 244 | 0.020 |
Why?
|
| Lipids | 1 | 2002 | 3316 | 0.020 |
Why?
|
| Isoenzymes | 1 | 1996 | 1689 | 0.020 |
Why?
|
| Fluorescein Angiography | 2 | 2009 | 1085 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 2895 | 0.020 |
Why?
|
| Lymphocyte Activation | 2 | 2020 | 5501 | 0.020 |
Why?
|
| Colon, Sigmoid | 1 | 1992 | 124 | 0.020 |
Why?
|
| Reactive Oxygen Species | 2 | 1997 | 2140 | 0.020 |
Why?
|
| Superoxides | 1 | 1992 | 383 | 0.020 |
Why?
|
| Solubility | 1 | 2013 | 1078 | 0.020 |
Why?
|
| Quinolones | 1 | 1994 | 387 | 0.020 |
Why?
|
| Zinc Compounds | 1 | 2010 | 35 | 0.020 |
Why?
|
| Ileum | 1 | 1993 | 558 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 3602 | 0.020 |
Why?
|
| Tranexamic Acid | 1 | 1993 | 173 | 0.020 |
Why?
|
| Collagen | 2 | 2010 | 2618 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2021 | 2747 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 1167 | 0.020 |
Why?
|
| Hemorheology | 1 | 2010 | 144 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 1996 | 2268 | 0.020 |
Why?
|
| Chemokine CCL7 | 1 | 2009 | 30 | 0.020 |
Why?
|
| Feathers | 1 | 2009 | 29 | 0.020 |
Why?
|
| Hydrodynamics | 1 | 2010 | 163 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 36532 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2013 | 931 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2013 | 1749 | 0.020 |
Why?
|
| Eicosapentaenoic Acid | 1 | 1993 | 565 | 0.020 |
Why?
|
| Hyperplasia | 2 | 2006 | 1144 | 0.020 |
Why?
|
| Enzyme Assays | 1 | 2009 | 102 | 0.020 |
Why?
|
| Fibrosis | 1 | 2016 | 2070 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1 | 2 | 2000 | 190 | 0.020 |
Why?
|
| Hematocrit | 1 | 2010 | 621 | 0.020 |
Why?
|
| Vitamin E | 1 | 1993 | 869 | 0.020 |
Why?
|
| Hot Temperature | 1 | 1995 | 1433 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 1997 | 1132 | 0.020 |
Why?
|
| Metabolome | 1 | 2016 | 1005 | 0.020 |
Why?
|
| Bacterial Toxins | 1 | 1994 | 924 | 0.020 |
Why?
|
| Cataract Extraction | 1 | 1992 | 464 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2009 | 254 | 0.020 |
Why?
|
| Thrombosis | 1 | 2002 | 2949 | 0.020 |
Why?
|
| Video Recording | 2 | 2007 | 969 | 0.020 |
Why?
|
| Ultrasonography | 2 | 2018 | 5993 | 0.020 |
Why?
|
| Autonomic Nervous System | 1 | 1992 | 706 | 0.020 |
Why?
|
| Biosensing Techniques | 1 | 2013 | 642 | 0.020 |
Why?
|
| Cell Death | 1 | 2012 | 1679 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 20125 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1761 | 0.020 |
Why?
|
| Surface Properties | 1 | 2010 | 1151 | 0.020 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2007 | 111 | 0.020 |
Why?
|
| Survival Rate | 1 | 2021 | 12795 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2009 | 602 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 2476 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 5849 | 0.020 |
Why?
|
| Water | 1 | 2013 | 1417 | 0.020 |
Why?
|
| Immunity, Mucosal | 1 | 2010 | 498 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2009 | 898 | 0.020 |
Why?
|
| Immune System | 1 | 2011 | 799 | 0.020 |
Why?
|
| Ischemia | 2 | 1995 | 1909 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2006 | 360 | 0.020 |
Why?
|
| Hydrostatic Pressure | 1 | 2006 | 98 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2007 | 562 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2000 | 618 | 0.020 |
Why?
|
| Models, Cardiovascular | 1 | 2011 | 979 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2010 | 1885 | 0.020 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2005 | 43 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2015 | 5881 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 6499 | 0.010 |
Why?
|
| Ephrin-B2 | 1 | 2004 | 40 | 0.010 |
Why?
|
| Sarcoma | 1 | 2016 | 1802 | 0.010 |
Why?
|
| Analysis of Variance | 3 | 2000 | 6203 | 0.010 |
Why?
|
| Collagen Type IV | 1 | 2004 | 124 | 0.010 |
Why?
|
| Treatment Outcome | 3 | 2021 | 65189 | 0.010 |
Why?
|
| Crohn Disease | 1 | 1997 | 2283 | 0.010 |
Why?
|
| Single-Cell Analysis | 1 | 2015 | 2536 | 0.010 |
Why?
|
| Leukocyte Rolling | 1 | 2004 | 69 | 0.010 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 950 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2013 | 2324 | 0.010 |
Why?
|
| Basement Membrane | 1 | 2004 | 349 | 0.010 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2004 | 158 | 0.010 |
Why?
|
| Membrane Transport Proteins | 1 | 2009 | 1028 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2015 | 9649 | 0.010 |
Why?
|
| Gamma Rays | 1 | 2004 | 324 | 0.010 |
Why?
|
| Ligation | 1 | 2004 | 444 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2012 | 2210 | 0.010 |
Why?
|
| Rheology | 1 | 2004 | 348 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 2004 | 752 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2008 | 1206 | 0.010 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2006 | 482 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 2003 | 251 | 0.010 |
Why?
|
| DNA Damage | 2 | 2007 | 2457 | 0.010 |
Why?
|
| Cytokines | 1 | 1998 | 7421 | 0.010 |
Why?
|
| Dipeptides | 1 | 2004 | 387 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 3750 | 0.010 |
Why?
|
| Lipid Peroxidation | 2 | 1993 | 275 | 0.010 |
Why?
|
| Bacterial Adhesion | 1 | 2003 | 306 | 0.010 |
Why?
|
| Zebrafish | 1 | 2013 | 3035 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2007 | 1742 | 0.010 |
Why?
|
| Brain | 2 | 2019 | 27178 | 0.010 |
Why?
|
| Genes, erbB-2 | 1 | 2002 | 160 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1993 | 822 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2004 | 793 | 0.010 |
Why?
|
| Colitis | 1 | 2010 | 1239 | 0.010 |
Why?
|
| Equipment Design | 1 | 2009 | 3481 | 0.010 |
Why?
|
| Graft Survival | 1 | 2011 | 3890 | 0.010 |
Why?
|
| Cell Count | 2 | 1995 | 1823 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2001 | 474 | 0.010 |
Why?
|
| Genes, Lethal | 1 | 2000 | 224 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2004 | 637 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2012 | 10070 | 0.010 |
Why?
|
| Angiostatins | 1 | 1999 | 64 | 0.010 |
Why?
|
| Colitis, Ulcerative | 1 | 1992 | 1915 | 0.010 |
Why?
|
| Ovariectomy | 1 | 2002 | 611 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 9524 | 0.010 |
Why?
|
| Plasminogen | 1 | 1999 | 144 | 0.010 |
Why?
|
| Neurons | 1 | 2019 | 9524 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2005 | 1744 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2005 | 1140 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2004 | 1718 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 2013 | 10261 | 0.010 |
Why?
|
| Antigens | 1 | 2004 | 1438 | 0.010 |
Why?
|
| Muscle Neoplasms | 1 | 2000 | 130 | 0.010 |
Why?
|
| Peptides | 1 | 2011 | 4331 | 0.010 |
Why?
|
| Image Enhancement | 1 | 2009 | 2858 | 0.010 |
Why?
|
| Pregnancy | 1 | 2020 | 30258 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2016 | 13039 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2009 | 5302 | 0.010 |
Why?
|
| Thrombospondin 1 | 1 | 1999 | 256 | 0.010 |
Why?
|
| Hindlimb | 1 | 2000 | 510 | 0.010 |
Why?
|
| Portal Pressure | 1 | 1997 | 62 | 0.010 |
Why?
|
| Melanoma | 2 | 2006 | 5719 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1999 | 522 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2000 | 11083 | 0.010 |
Why?
|
| Endothelium, Lymphatic | 1 | 1997 | 63 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1999 | 1430 | 0.010 |
Why?
|
| Receptors, Endothelin | 1 | 1996 | 56 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1997 | 412 | 0.010 |
Why?
|
| Microspheres | 1 | 1999 | 773 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2006 | 2844 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 1997 | 623 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1997 | 415 | 0.010 |
Why?
|
| Clone Cells | 1 | 1999 | 1672 | 0.010 |
Why?
|
| Concanavalin A | 1 | 1995 | 191 | 0.010 |
Why?
|
| CHO Cells | 1 | 1998 | 1372 | 0.010 |
Why?
|
| Blood Pressure | 2 | 2004 | 8532 | 0.010 |
Why?
|
| Antimetabolites | 1 | 1995 | 127 | 0.010 |
Why?
|
| Gene Targeting | 1 | 1998 | 841 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1997 | 607 | 0.010 |
Why?
|
| Peptidoglycan | 1 | 1997 | 246 | 0.010 |
Why?
|
| Biological Transport | 1 | 1999 | 2081 | 0.010 |
Why?
|
| United States | 1 | 2023 | 72898 | 0.010 |
Why?
|
| Cricetinae | 1 | 1998 | 2411 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2000 | 2228 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 14652 | 0.010 |
Why?
|
| Shiga Toxin 1 | 1 | 1994 | 42 | 0.010 |
Why?
|
| Genotype | 1 | 2009 | 13024 | 0.010 |
Why?
|
| Streptococcus pyogenes | 1 | 1997 | 295 | 0.010 |
Why?
|
| Oxidative Phosphorylation | 1 | 1996 | 502 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 1994 | 181 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1997 | 657 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 18071 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1995 | 561 | 0.010 |
Why?
|
| Electroshock | 1 | 1994 | 120 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2000 | 1870 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1996 | 462 | 0.010 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1995 | 445 | 0.010 |
Why?
|
| Ovalbumin | 1 | 1995 | 674 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 2004 | 2128 | 0.010 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1995 | 287 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1997 | 1886 | 0.010 |
Why?
|
| Luminol | 1 | 1992 | 6 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1995 | 2163 | 0.010 |
Why?
|
| Xanthine Oxidase | 1 | 1993 | 69 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 1993 | 318 | 0.010 |
Why?
|
| Sodium Azide | 1 | 1992 | 24 | 0.010 |
Why?
|
| Venules | 1 | 1993 | 162 | 0.010 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 1992 | 110 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1997 | 17594 | 0.010 |
Why?
|
| Radiation | 1 | 1992 | 48 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2006 | 6255 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 1992 | 123 | 0.010 |
Why?
|
| Picibanil | 1 | 1992 | 10 | 0.010 |
Why?
|
| Azides | 1 | 1992 | 120 | 0.010 |
Why?
|
| Biopsy | 2 | 1996 | 6763 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1997 | 4165 | 0.010 |
Why?
|
| Lipid Peroxides | 1 | 1991 | 73 | 0.010 |
Why?
|
| Allopurinol | 1 | 1993 | 203 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 1999 | 1352 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 3690 | 0.010 |
Why?
|
| RNA | 1 | 2001 | 2717 | 0.010 |
Why?
|
| Fura-2 | 1 | 1991 | 107 | 0.010 |
Why?
|
| Diet | 1 | 2009 | 8086 | 0.010 |
Why?
|
| Stomach | 1 | 1995 | 699 | 0.010 |
Why?
|
| Amino Acids | 1 | 1997 | 1709 | 0.010 |
Why?
|
| Proton Pump Inhibitors | 1 | 1996 | 553 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 1993 | 686 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1996 | 2505 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 30196 | 0.010 |
Why?
|
| Membrane Lipids | 1 | 1991 | 240 | 0.010 |
Why?
|
| Lysosomes | 1 | 1996 | 932 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1996 | 2845 | 0.010 |
Why?
|
| Epithelium | 1 | 1994 | 1599 | 0.010 |
Why?
|
| Phospholipids | 1 | 1993 | 776 | 0.010 |
Why?
|
| Calcium | 2 | 1993 | 5767 | 0.000 |
Why?
|
| Edema | 1 | 1993 | 760 | 0.000 |
Why?
|
| Drug Interactions | 1 | 1993 | 1417 | 0.000 |
Why?
|
| Algorithms | 1 | 2009 | 14071 | 0.000 |
Why?
|
| Receptors, Cell Surface | 1 | 1997 | 2817 | 0.000 |
Why?
|
| Peptide Fragments | 1 | 1999 | 5125 | 0.000 |
Why?
|
| Pyrazines | 1 | 1992 | 1204 | 0.000 |
Why?
|
| Adult | 4 | 2007 | 223038 | 0.000 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1995 | 4405 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 1995 | 4778 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1993 | 13400 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 2004 | 15651 | 0.000 |
Why?
|
| Aged | 2 | 1996 | 171114 | 0.000 |
Why?
|
| Middle Aged | 2 | 1996 | 223004 | 0.000 |
Why?
|